Skip to Content
Merck
  • Enhanced enterovirus 71 virus-like particle yield from a new baculovirus design.

Enhanced enterovirus 71 virus-like particle yield from a new baculovirus design.

Biotechnology and bioengineering (2015-05-23)
Shih-Yeh Lin, Chia-Tsui Yeh, Wan-Hua Li, Cheng-Ping Yu, Wen-Chin Lin, Jyh-Yuan Yang, Hsueh-Ling Wu, Yu-Chen Hu
ABSTRACT

Enterovirus 71 (EV71) is responsible for the outbreaks of hand-foot-and-mouth disease in the Asia-Pacific region. To produce the virus-like particle (VLP) vaccine, we previously constructed recombinant baculoviruses to co-express EV71 P1 polypeptide and 3CD protease using the Bac-to-Bac(®) vector system. The recombinant baculoviruses resulted in P1 cleavage by 3CD and subsequent VLP assembly in infected insect cells, but caused either low VLP yield or excessive VLP degradation. To tackle the problems, here we explored various expression cassette designs and flashBAC GOLD™ vector system which was deficient in v-cath and chiA genes. We found that the recombinant baculovirus constructed using the flashBAC GOLD™ system was insufficient to improve the EV71 VLP yield. Nonetheless, BacF-P1-C3CD, a recombinant baculovirus constructed using the flashBAC GOLD(TM) system to express P1 under the polh promoter and 3CD under the CMV promoter, dramatically improved the VLP yield while alleviating the VLP degradation. Infection of High Five(TM) cells with BacF-P1-C3CD enhanced the total and extracellular VLP yield to ≈268 and ≈171 mg/L, respectively, which enabled the release of abundant VLP into the supernatant and simplified the downstream purification. Intramuscular immunization of mice with 5 μg purified VLP induced cross-protective humoral responses and conferred protection against lethal virus challenge. Given the significantly improved extracellular VLP yield (≈171 mg/L) and the potent immunogenicity conferred by 5 μg VLP, one liter High Five(TM) culture produced ≈12,000 doses of purified vaccine, thus rendering the EV71 VLP vaccine economically viable and able to compete with inactivated virus vaccines.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydroxyapatite, nanopowder, <200 nm particle size (BET), contains 5 wt. % silica as dopant, synthetic
Sigma-Aldrich
Hydroxyapatite, nanoparticles, dispersion, 10 wt. % in H2O, <200 nm particle size (BET)
Sigma-Aldrich
Hydroxyapatite, purum p.a., ≥90% (as Ca3(PO4)2, KT)
Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine, ≥98.0% (NT)
Sigma-Aldrich
Hydroxyapatite, nanopowder, <200 nm particle size (BET), ≥97%, synthetic
Sigma-Aldrich
Sulfuric acid, 99.999%
Sigma-Aldrich
Hydroxyapatite, synthetic, 99.8% trace metals basis (excludes Mg)
Sigma-Aldrich
Hydroxyapatite, reagent grade, powder, synthetic
Sigma-Aldrich
Hydroxyapatite, puriss., meets analytical specification of Ph. Eur., BP, FCC, E341, ≥90% (calculated on glowed substance)
Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine, ≥99%
Sigma-Aldrich
Calcium phosphate tribasic, 34.0-40.0% Ca basis
Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine, tablet, 1 mg substrate per tablet
Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine, ≥98% (TLC)
Sigma-Aldrich
Calcium phosphate tribasic, suitable for plant cell culture, BioReagent, powder
Sigma-Aldrich
Anti-Enterovirus 71 Antibody, cross-reacts with Coxsackie A16, clone 422-8D-4C-4D, ascites fluid, clone 422-8D-4C-4D, Chemicon®